 |
|
|
| |
PHARMACOKINETIC INTERACTIONS OF FALDAPREVIR AND DELEOBUVIR AND THEIR INDIVIDUAL AND COMBINED EFFECT ON SELECTED CYTOCHROME P450 PROBE SUBSTRATES IN PATIENTS INFECTED WITH GENOTYPE-1 HCV
|
| |
| |
Reported by Jules Levin
AASLD Nov 1-4 Wash DC
C. Cooper1, B Conway2, W Ghesquiere3, R Lalonde4, A Ramji5, N Chandok6, E Tam7, R Sane8, N Ting8, FJ Mensa8, M Elgadi9, JP Sabo8
1Division of Infectious Diseases, The Ottawa Hospital Research Institute, Ottawa, ON, Canada; 2Vancouver Infectious Diseases Centre, Vancouver, BC, Canada; 3Division of Infectious Diseases, University of British Columbia, Victoria, BC, Canada; 4McGill University Health Centre, Montreal, QC, Canada; 5Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada; 6Division of Gastroenterology, University of Western Ontario, London, ON, Canada; 7Lair Centre, Vancouver, BC, Canada; 8Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 9Boehringer Ingelheim Canada Ltd/Ltée, Burlington, ON, Canada
|
| |
|
|
|
|
|
